-
Mashup Score: 2FDA Grants 510(k) Clearance to Sebiaβs FLC Kappa, Lambda Assays for MM Diagnosis | Blood Cancers Today - 6 hour(s) ago
Sebiaβs free light chain (FLC) kappa and lambda assays have 510(k) clearance.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 1Low-Dose Azacitidine Plus Venetoclax Is Effective Maintenance for AML | Blood Cancers Today - 14 hour(s) ago
Low-dose azacitidine plus venetoclax was a feasible maintenance regimen in AML after intensive or low-intensity induction therapy.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 2Hematologic Oncology News | Blood Cancers Today - 1 day(s) ago
Blood Cancers Today provides hematologists and oncologists with news, education, and information relevant to their patients and practices, featuring exclusive expert interviews.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 5Shyam Patel, MD, PhD, Explains the Patterns of Progression from CHIP to Myeloid Neoplasms | Blood Cancers Today - 1 day(s) ago
The average rate of progression for CHIP to MDS or AML is about 1% per year, Dr. Patel explained.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 10Krish Patel, MD, Talks Gilteritinib, Other Novel Frontline Therapies in DLBCL | Blood Cancers Today - 1 day(s) ago
“Having something that could cure patients after failing CAR-T is huge,β host Dr. Chadi Nabhan said during the episode.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
π¨ Out now! The latest "HemOnc Pulse" episode with @chadinabhan featuring @KrishPatelMD, of @ProvSwedCancRes. ποΈ They discuss novel frontline therapies in the lymphoma space, including the bispecific antibody gilteritinib. #DLBCL π§ Listen here! https://t.co/AyJlXtikzZ https://t.co/ECgfNlyaYc
-
-
Mashup Score: 3MRD Appears Optimal for Allogeneic Transplant Patient Selection in AML | Blood Cancers Today - 2 day(s) ago
MRD status after induction chemotherapy predicted benefit from allogeneic transplant in patients with NPM1-mutated AML.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
β MRD status after induction chemotherapy predicted benefit from allogeneic transplant in patients with NPM1-mutated #AML in first complete remission. Read more about the study, led by Jad Othman, MD, of @NthSydHealth, and published in @BloodJournal. π https://t.co/xsjpO0uU7A https://t.co/PXLrcYMRpy
-
-
Mashup Score: 1
Extrachromosomal DNA was highly expressed in 18 DLBCL cell lines, especially relapsed or refractory cases, and may function as a powerful prognostic indicator.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
A multiomics analysis shows how inhibiting a gene signaling pathway might work in treating #DLBCL. Researchers theorize that circular DNA independent of chromosomes is involved in cancer cell development, disease heterogeneity, and drug resistance. π§¬π° https://t.co/eaQhx5hwfb https://t.co/xVQE5m2hWA
-
-
Mashup Score: 17Live In Chicago It's The HemOnc Pulse | Blood Cancers Today - 2 day(s) ago
“The HemOnc Pulse” will be live in Chicago on May 3-4 with host Chadi Nabhan, MD, MBA, FACP, as he curates all the latest news in hematology oncology with leaders in the field.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
π¬ Live in Chicago, it's "The HemOnc Pulse!" π Get ready for "The HemOnc Pulse" Live on May 3-4 with @chadinabhan as he curates all the latest news in hematology oncology with leaders in the field like @Rfonsi1, @sanamloghavi, and more! β‘οΈ Learn more: https://t.co/UMNlK1zFzS https://t.co/S1Eq9uani8
-
-
Mashup Score: 14'The HemOnc Pulse' Live: Dr. Zeidan Talks MDS Panel, Other Exciting Sessions | Blood Cancers Today - 2 day(s) ago
Dr. Zeidan will be participating in the myelodysplastic syndromes panel on the second day of the event
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 14'The HemOnc Pulse' Live: Dr. Zeidan Talks MDS Panel, Other Exciting Sessions | Blood Cancers Today - 2 day(s) ago
Dr. Zeidan will be participating in the myelodysplastic syndromes panel on the second day of the event
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
There's no shortage of FDA news this week on BCT! The @US_FDA has granted 510(k) clearance to @SebiaUS's FLC kappa and lambda assays to aid in the diagnosis and monitoring of #MultipleMyeloma and AL amyloidosis. π° Read more: https://t.co/LzzYfWxg8h https://t.co/nxXTNzACMP